On February 17, the Shanghai Sunshine Pharmaceutical Procurement Network issued the Notice on the Filling and Reporting of Information on the Eighth Batch of Nationally-Organized Drug Centralized Procurement (hereinafter referred to as the "Notice"). Since February 20, 2023, the Joint Procurement Office has carried out the filling and reporting of information on the Eighth Batch of Nationally-Organized Drug Centralized Procurement. According to the published scope of drug filling, a total of 41 varieties and 181 specifications of drugs have entered the centralized purchase, such as Agatroban injection, amlodipine atorvastatin oral constant release form, sodium valproate injection, etc., covering the treatment fields of systemic anti-infective drugs, cardiovascular and cerebrovascular system drugs, blood and hematopoietic system drugs, nervous system drugs, etc. Deng Zhidong, general manager of Hainan Boao Medical Technology Co., Ltd., told the Securities Daily, "The eighth batch of national centralized procurement, with rich categories and many participants, has further improved the entry threshold, and the selected varieties have decreased compared with last year, but the number of selected varieties has increased year-on-year, and the competition among pharmaceutical enterprises has become more intense, Compared with previous national centralized purchase, the proportion exceeded 60% for the first time; There are 11 oral regular release dosage forms; There are 1 granule, 1 sustained-release and controlled-release dosage form and 1 oral solution. In response, Deng Zhidong said, "The proportion of injectable drugs included in this centralized purchase is relatively large. Such drugs rely on hospital channels and account for a relatively large share in the chemical drug market." It is widely believed in the industry that with the promotion of the consistency evaluation of generic drugs for chemical drug injections, the number of over-evaluated drugs has increased significantly, and the competition for centralized purchase of related varieties may become fierce. From the perspective of treatment field, systemic anti-infective drugs are the largest number of drugs collected this time, including amoxicillin and clavulanic acid oral regular release dosage form, amoxicillin and clavulanic acid injection, amtreonam injection, ornidazole injection and other varieties. There are also 7 and 6 varieties of cardio-cerebrovascular system drugs, blood and hematopoietic system drugs included in the centralized purchase. According to the statistics of the intranet, among the anti-infective drugs for systemic use, there is fierce competition among the varieties of ornidazole injection, metronidazole sodium chloride injection, cefotaxime injection, and cefoxitin injection, with more than 10 drug companies (including the original drug companies) having been evaluated. Taking ornidazole injection as an example, as of February 19, the official website of the State Food and Drug Administration showed that there were 31 approvals for ornidazole injection in China, involving 15 pharmaceutical enterprises including Shijiazhuang No.4 Pharmaceutical Co., Ltd., Beijing Shuanglu Pharmaceutical Co., Ltd., Hunan Warner Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd. There are also 7 pharmaceutical enterprises that can compete with the systemic anti-infective drug cefoperazone sulbactam injection. Pfizer is the original manufacturer of this product, with a market share of more than 80%. In addition, there are more than 10 evaluated pharmaceutical enterprises (including the original research pharmaceutical enterprises) for the varieties of tranexamic acid injection, sodium valproate injection and enoxaparin injection. According to the public information of local pharmaceutical enterprises participating in many large variety competitions, the eighth batch of national centralized procurement varieties involves more than 20 original pharmaceutical enterprises, and foreign pharmaceutical enterprises such as Pfizer, Sanofi, AstraZeneca, Roche, Weicai, MSD and so on are listed. Among them, Pfizer has four original research